SPS2, for example, exploits the Se dependency of certain cancers, such as breast cancer, lymphoma, and melanoma by disrupting selenoprotein synthesis and inducing toxic selenide accumulation, which selectively targets cancer cells without affecting normal cells [71]. The gene discussed is SELENOS; the disease is breast carcinoma.